Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Donato Milanese – page 35

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Donato Milanese at a glance
2 835
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Squamous cell carcinoma of skin

Recruiting

A study of onfekafusp alfa and bifikafusp alfa injected into tumors for patients with advanced skin squamous cell cancer who did not respond to or could not tolerate previous treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Basal cell carcinoma

Recruiting

Study of bifikafusp alfa and onfekafusp alfa injected into tumors for patients with locally advanced basal cell carcinoma who progressed on or cannot tolerate systemic treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Basal cell carcinoma

Recruiting

Testing bifikafusp alfa and onfekafusp alfa injections in patients with locally advanced basal cell carcinoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Hereditary spastic paraplegia

Recruiting

Testing Gene Therapy AAV9/AP4M1 in Patients with Hereditary Spastic Paraplegia Type 50

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Melpida
  • Sponsor:Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii

Dilated cardiomyopathy

Recruiting

A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.

Adenocarcinoma pancreas

Recruiting

A Study of Olaparib Maintenance Treatment for Patients with Metastatic Pancreatic Cancer That Responded to First-Line Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Universita' Degli Studi Di Verona

Transitional cell carcinoma metastatic

Recruiting

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

MELAS syndrome+2

Recruiting

A study testing sonlicromanol in adults with genetically confirmed mitochondrial DNA 3243A>G variant causing mitochondrial disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Sonlicromanol
  • Sponsor:Khondrion B.V.

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Chronic lymphocytic leukaemia+2

Recruiting

A Study of Zanubrutinib for Patients with Anti-MAG Antibody Neuropathy Associated with Blood Disorders or Abnormal Protein in the Blood

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Azienda Ospedaliera di Padova

Endometrial cancer

Recruiting

A Study of Inavolisib for Patients with Advanced Endometrial Cancer Who Have PIK3CA Gene Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

  • Heart Failure Management
  • Cardiac Surgery Outcomes
  • Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

  • Hereditary Angioedema Treatments
  • Chronic Urticaria Management
  • Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.